DUAL-REGISTERED PROTOCOL // OSF PRE-REGISTERED (DOI: 10.17605/OSF.IO/VPS9D) · CLINICALTRIALS.GOV PRS IN PROGRESS · PROTOCOL ID: DS-CLIN-2026-ONCO-SHIELD · PLANNED N = 10,000
ONCO-SHIELD™ Registry.
Protecting bone marrow resilience during chemotherapy.
Over 40% of chemotherapy patients suffer debilitating treatment delays, dose reductions, or life-threatening febrile neutropenia nadirs. ONCO-SHIELD™ is a prospective decentralized clinical registry ($N=10,000$) modeling hematologic recovery curves and multi-drug pharmacokinetic interactions to sustain full chemotherapy Relative Dose Intensity (RDI ≥ 85%). Participation in the clinical registry is 100% Free.
RESOLVE in the United States: in preparation (IRB submission in preparation, the first country to open).
Registry Strata
Three Core Supportive Oncology Cohorts
Solid Tumors on Multi-Agent Chemotherapy
Breast, colorectal, lung, and ovarian cancer patients undergoing standard-of-care cytotoxic regimens (e.g. FOLFOX, AC-T, Carboplatin/Paclitaxel).
Hematologic Malignancies & Myelosuppression
Lymphoma and multiple myeloma patients receiving intensive marrow-suppressive regimens, serial tracking of platelet and neutrophil recovery kinetics.
Immunotherapy & Targeted Antibody Regimens
Checkpoint inhibitor (anti-PD-1, anti-CTLA-4) and ADC therapies, mapping immune-related adverse events (irAE) and systemic mucosal resilience.
From routine care, ordered by each participant's own physicians, the registry also records urine organic acids, a metagenomic stool profile and the full list of medicines and supplements.
DeepSensi DCT
